

University of Dundee

An Unexplored Pharmacologic/Diagnostic Strategy for Peri-Implantitis

Golub, Lorne M.; Räisänen, Ismo T.; Sorsa, Timo; Preshaw, Philip M.

Published in:
Diagnostics

DOI:
[10.3390/diagnostics10121050](https://doi.org/10.3390/diagnostics10121050)

Publication date:
2020

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Golub, L. M., Räisänen, I. T., Sorsa, T., & Preshaw, P. M. (2020). An Unexplored Pharmacologic/Diagnostic Strategy for Peri-Implantitis: A Protocol Proposal. *Diagnostics*, 10(12), Article 1050.
<https://doi.org/10.3390/diagnostics10121050>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Commentary

An Unexplored Pharmacologic/Diagnostic Strategy for Peri-Implantitis: A Protocol Proposal

Lorne M. Golub ¹, Ismo T. Räisänen ^{2,*} , Timo Sorsa ^{2,3} and Philip M. Preshaw ^{4,5}

¹ Department of Oral Biology and Pathology, School of Dental Medicine, Health Sciences Center, Stony Brook University, Stony Brook, NY 11794, USA; Lorne.Golub@stonybrookmedicine.edu

² Department of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, PO Box 63 (Haartmaninkatu 8), FI-00014 Helsinki, Finland; timo.sorsa@helsinki.fi

³ Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden

⁴ National University Centre for Oral Health, Faculty of Dentistry, National University of Singapore, Singapore 119077, Singapore; philip.preshaw@nus.edu.sg

⁵ School of Dental Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK

* Correspondence: ismo.raisanen@helsinki.fi;

Received: 28 October 2020; Accepted: 3 December 2020; Published: 5 December 2020



Abstract: Dental implants are widely utilized for the replacement of missing teeth and are increasingly being placed in patients with systemic diseases, as well as in those who are medically healthy. Furthermore, it is recognized that peri-implant mucositis and peri-implantitis are highly prevalent, affecting large numbers of patients with implants, and it is pertinent to consider whether there may be any systemic impact of these conditions, given that there are known links between periodontitis and a number of chronic inflammatory diseases. In this article, we propose that the potential systemic complications of peri-implant diseases should be investigated in future clinical research, together with studies to identify whether systemically-administered host modulation therapies (HMTs) may be of benefit in the treatment of peri-implant diseases. These “HMTs” may prove a useful adjunct to routinely employed debridement and disinfection protocols, as well as potentially being of benefit in reducing risks of systemic complications. We also consider the use of chair-side diagnostic tests for active matrix metalloproteinase-8 (aMMP-8) in the detection of peri-implant disease given the ability of such tests to detect active tissue breakdown associated with peri-implantitis and periodontitis before conventional clinical and radiographic measurements indicate pathologic changes. These novel diagnostic and therapeutic strategies are relevant to consider as they may improve the management of peri-implant disease (beyond local debridement procedures), especially in those patients in whom systemic inflammation might be of concern.

Keywords: dental implants; peri-implant mucositis; peri-implantitis; periodontitis; host modulation therapies; matrix metalloproteinases; matrix metalloproteinase 8; aMMP-8

Dental implants have become a dominant treatment strategy to enhance oral function and esthetics in partially and completely edentulous patients. Increasingly, however, implants are being placed not only in medically healthy individuals, but also in those with systemic disorders such as diabetes, cardiovascular and gastrointestinal disease [1–3]. Although many case reports of implant placement in medically compromised patients have been described as successful, it has also been stated that, currently, “there is insufficient evidence to determine whether dental implants can remain functionally stable” over prolonged periods of time in systemically compromised patients [1] and this is an area of ongoing research.

While the issue of local (oral) inflammation in dental implantology has been extensively addressed in a number of studies (see Javed and Romanos [1] for a review), we now consider that an additional question should be posed; that is, what is the risk, if any, that peri-implant disease may induce and/or contribute to systemic inflammation? This question is relevant because, firstly, the prevalence rates of peri-implant mucositis and peri-implantitis are high [4]; it has been estimated that peri-implant mucositis affects about 43%, and peri-implantitis 22%, of patients with implants [5]. Secondly, the inflammatory response in peri-implantitis appears to produce larger [6], and more intense and tissue-destructive lesions than that in periodontitis, with bone loss occurring in a non-linear, accelerating pattern [7]. Regarding mechanistic support of this enhanced pathology, it has been reported that peri-implant sulcular fluid (PISF) contains higher levels of leukocyte-type collagenase (matrix metalloproteinase-8, MMP-8) than gingival crevicular fluid (GCF) around natural teeth [8]. Furthermore, peri-implant sites often have much larger inflammatory lesions with significantly higher proportions, numbers and densities of cells part of both the innate and the adaptive host response, namely the plasma cells, macrophages and neutrophils compared with periodontitis sites [6]. Furthermore, higher numbers of M1 tissue-destructive macrophages (rather than M2 anti-inflammatory macrophages) have been found to infiltrate peri-implantitis lesions compared to those with periodontitis [9]. Moreover, it is well known that systemic inflammation is associated with increased risk of cardiovascular and other systemic diseases such as diabetes [5,10,11]. It is also clear that diabetes and smoking, both of which have impacts on systemic inflammation, are key risk factors for periodontal and peri-implant diseases. Thus, upregulated systemic (as well as local) inflammation likely underpins the links between periodontitis (and possibly peri-implantitis, though this has yet to be demonstrated) and diabetes and cardiovascular diseases.

Accordingly, we now propose that the potential systemic complications of peri-implant diseases should be considered by the profession and investigated in appropriately designed clinical trials. If such an impact is confirmed, this would suggest the need for more intensive treatment of peri-implantitis, which would include not only commonly employed local debridement and disinfection protocols, but also might incorporate currently available (and future) systemically-administered (oral route) host modulation therapies (HMTs); those currently available were reviewed recently and are briefly discussed below [10]. This proposed “combination therapy” may not only enhance the efficacy of conventional disinfection treatment protocols for peri-implantitis but may also reduce the risks of any systemic complications as well.

Thus, we suggest that in future studies of peri-implantitis, patients should be analyzed for well-established biomarkers of systemic inflammation (for example, high sensitivity C-reactive protein (hsCRP), cytokines such as interleukin (IL)-6, and collagenolytic enzymes such as MMP-8, MMP-9) in their blood samples, before and after local debridement procedures, and in combination with HMT. Evidence to support the potential benefits of this approach has already been demonstrated. In an National Institutes of Health (NIH)-sponsored, double-blind, placebo-controlled study of 128 post-menopausal women, who exhibited both local (periodontitis) and systemic (osteopenia) bone loss, a 2 year regimen of this proposed therapeutic strategy significantly reduced biomarkers of systemic inflammation (hsCRP and MMP-9 in their blood samples), as well as reducing local (GCF) and systemic (blood) levels of collagenolytic enzymes (MMP-8) and bone resorption biomarkers (ICTP, carboxy-terminal telopeptide fragments of type I collagen) [10,12–14]. In an earlier double-blind placebo-controlled clinical trial of patients with severe cardiovascular disease (acute coronary syndrome, ACS), a similar HMT (non-antibiotic-dose doxycycline) demonstrated efficacy in reducing biomarkers of systemic inflammation after a 6 month regimen [15,16]. Moreover, the clinical importance of this proposed strategy is based on numerous clinical and epidemiologic studies in cardiology that have consistently demonstrated that systemic inflammation (characterized by elevated levels of hsCRP, cytokines, and MMPs in the circulation) is a greater risk for myocardial infarction than elevated cholesterol [17,18].

An additional innovation to consider is the development of diagnostic chair-side tests for active MMP-8 (aMMP-8), the presence of which indicates active periodontal tissue breakdown. Historically, this was suggested in 1974–1976 in a series of articles that described the detection and “characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival diseases” (i.e., periodontitis, pericoronitis) in humans [19–22]. Since that time, a number of potential targets have been investigated for utility in the detection and monitoring of periodontitis, such as MMP-8, MMP-13, MMP-14, myeloperoxidase and azurocidin [23]. These studies have consistently identified MMP-8 as a most promising candidate for oral fluid (GCF, PISF, mouthrinse, saliva) point-of-care diagnostics and for evaluating disease progression and treatment outcomes [24]. In parallel, a number of both qualitative and quantitative technologies for analysis of MMP-8 levels in oral samples have been developed, including immunofluorometric assays (IFMA), an MMP-8 specific immunochromatographic dip-stick test, sandwich-based immunoassay systems (MMP-8 DentoAnalyzer device), and conventional MMP-8 ELISAs (enzyme-linked immunosorbent assays) [25].

Given the importance of MMP-8, and more specifically aMMP-8 in the pathogenesis of periodontal diseases, more recently, chair-side tests (government-approved in Europe) have been developed that can measure aMMP-8 levels in PISF, GCF and mouthrinse, and have been validated in studies conducted in the USA, Africa, and Europe [26–31]. Its advantage, beyond traditional diagnostic procedures (e.g., bleeding on probing, pocket depth), is enhanced diagnostic sensitivity and specificity, including the ability to predictively detect peri-implantitis and periodontitis before clinical and radiographic measurements indicate pathologic changes [26–31]. Further studies are required to investigate the utility of this test in different patient populations, such as smokers and non-smokers, given that GCF and serum MMP-8 levels are known to vary between smokers and non-smokers [24,32]. It is also necessary to develop reproducible reference ranges, for example to distinguish between health, gingivitis, or periodontitis, but perhaps more usefully to identify (with adequate sensitivity and specificity) disease progression, or periodontal stability following successful treatment.

Recently, Sorsa et al. [33] suggested reference ranges for aMMP-8 in mouthrinse (measured by PerioSafe® chair-side/point-of-care aMMP-8 test [29,33]) in regard to grading a periodontitis patient [34]. Similarly, aMMP-8 reference ranges can be proposed for grading peri-implantitis patients and their risk of disease progression. Based on a recent study by Lähteenmäki et al. [31], a cut-off of 20 ng/mL for aMMP-8 levels measured in PISF by ImplantSafe® chair-side/point-of-care aMMP-8 test identified all 26 peri-implantitis patients and 26 healthy dental implant controls correctly. Furthermore, the aMMP-8 chair-side test was more accurate than other potential biomarkers such as neutrophil elastase, myeloperoxidase, pro and active forms of MMP-9 and bleeding on probing [31]. With the same study group, we have investigated this further and found that the aMMP-8 chair-side test was also more accurate than calprotectin and gelatinases (25–50 kDa, 95–150 kDa, over 150 kDa and total gelatinolytic activity) (see Figure 1). Thus, based on the current evidence, grading the risk of periodontal and peri-implant disease progression by utilizing aMMP-8 can be summarized: low aMMP-8 levels are associated with periodontal and peri-implant health and low risk of disease progression, while elevated levels indicate elevated risk of periodontitis and peri-implantitis and their progression (Table 1) [26–31,33]. It should be noted that the ImplantSafe® and PerioSafe® lateral flow immunotests utilize the same antibody for aMMP-8 measurements [25,29,33], because different antibodies with differing sensitivities and specificities to target MMP-8 isotypes can give significantly different aMMP-8 results. For example, previously, Sorsa et al. [25] and Nieminen et al. [35] found a strong correlation between IFMA and ELISA assays for aMMP-8 measurements with this same antibody [25,29,33], but not with Amersham ELISA kit, which utilizes a different antibody.




Figure 1. Receiver operating characteristic (ROC) analysis illustrating the diagnostic ability of active matrix metalloproteinase-8 (aMMP-8) chair-side/point-of-care (PoC) test and selected potential biomarkers: polymorphonuclear leukocyte (PMN)/neutrophil elastase, calprotectin, gelatinases (25–50 kDa, 95–150 kDa, over 150 kDa and total gelatinolytic activity) and bleeding on probing (BOP) to discriminate peri-implantitis from healthy dental implant (26 peri-implant and 26 healthy dental implant patients). aMMP-8 PoC test and selected potential biomarkers were assessed as described previously [31]. This figure has been constructed by authors ITR and TS based on the same study group as described in Lähteenmäki et al. and further extends their results [31].

Table 1. Grading of peri-implantitis and periodontitis and the risk of their progression (modified from Tonetti et al. [34] and Sorsa et al. [33]) by active matrix metalloproteinase-8 (aMMP-8) as the main biomarker for active/progressing peri-implant and periodontal diseases. Here, the aMMP-8 cut-offs for peri-implantitis and periodontitis are applicable to ImplantSafe® and PerioSafe® lateral flow aMMP-8 point-of-care immunotests utilizing the same antibody in the aMMP-8 measurements [25,29,33].

Grading of the Risk of Disease Progression in Peri-Implantitis and Periodontitis by aMMP-8			
		No or Low Risk	Elevated Risk
Indicators of active periodontal tissue destruction/bone loss/clinical attachment loss	Peri-implant sulcular fluid, gingival crevicular fluid, mouthrinse	aMMP-8 concentration below 20 ng/mL	aMMP-8 concentration ≥20 ng/mL

Clearly, much research is yet to be undertaken to evaluate the potential use of diagnostic chair-side tests in identifying the onset and progression of peri-implant diseases. Peri-implantitis is a complex chronic inflammatory condition, in which multiple systemic (e.g., smoking, diabetes), behavioral (e.g., patient compliance with oral hygiene and maintenance visits), local (e.g., presence of periodontitis) and prosthetic (e.g., excess cement, poorly fitting prostheses, micro gaps at the implant–abutment interface) all contribute to the risk of developing the disease [36,37]. We also recognize that a beneficial impact of the novel therapeutic and diagnostic strategies, described above, in reducing local and systemic inflammation in patients with periodontitis (which often affects multiple teeth), might not produce a detectable similar systemic response in patients with peri-implantitis, since these individuals typically have fewer numbers of implant placements. However, such studies are likely to advance our profession’s management of peri-implant disease (beyond local debridement procedures), especially in

those patients in whom systemic inflammation might be of concern. Related to the dominance of innate immune responses and defense responses in peri-implantitis instead of bacterial response systems [38], HMTs, as an adjunct to debridement procedures (and combined with real-time PISF diagnostics), may provide an effective and comprehensive therapeutic strategy. The more intense inflammatory character of peri-implantitis lesions pose an elevated risk of rapid progression that underscores the importance of timely and effective disease diagnostics and treatment [39].

Author Contributions: L.M.G., I.T.R., T.S. and P.M.P. contributed to conception and interpretation, drafted, and critically revised the manuscript, and approved the final submitted version. I.T.R. and T.S. also contributed to data curation, formal analysis, investigation, and visualization. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the following institutions. For Lorne M. Golub, studies referred to in this review were supported in part by NIDCR/NIH grants R37-DE03987, R01DE012872, K16DE00275, K11DE00363, R41DE024946, R42DE024964, and by Johnson & Johnson; CollaGenex Pharmaceuticals, Inc.; Galderma R&D; Kroc Foundation Med. Res.; Traverse Biosciences Inc.; New York State Diabetes Association, and by Stony Brook Research account #1050308-37298. For Timo Sorsa, his studies were supported by grants from the University of Helsinki Research Foundation TYH2016251, TYH2017251, TYH2018229, TYH2019314, Y101SL017, Y1014SL018, Y1014SULE1, Helsinki, Finland and the Karolinska Institute, Stockholm, Sweden. For Philip M. Preshaw, he has received research funding, honoraria and travel grants from Philips Research and from Colgate.

Conflicts of Interest: Lorne M. Golub is listed as an inventor on several patents on host-modulation therapies and these have been fully assigned to his institution, Stony Brook University, State University of New York. Timo Sorsa is an inventor on several patents on new diagnostic tests described herein (US-patents 5652223, 5736341, 5866432, 6143476, 20170023571A1, WO 2018/060553 A1, 10 488 415 B2, and a Japanese patent 2016-554676). Philip M. Preshaw and Ismo T. Räisänen declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Javed, F.; Romanos, G.E. *Evidence-Based Implant Dentistry and Systemic Conditions*, 1st ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2018.
2. Elsubeihi, E.S.; Zarb, G.A. Implant prosthodontics in medically challenged patients: The University of Toronto experience. *J. Can. Dent. Assoc.* **2002**, *68*, 103–108.
3. Nobre Mde, A.; Maló, P.; Gonçalves, Y.; Sabas, A.; Salvado, F. Outcome of dental implants in diabetic patients with and without cardiovascular disease: A 5-year post-loading retrospective study. *Eur. J. Oral Implantol.* **2016**, *9*, 87–95.
4. Giannobile, W.V.; Lang, N.P. Are Dental Implants a Panacea or Should We Better Strive to Save Teeth? *J. Dent. Res.* **2016**, *95*, 5–6. [[CrossRef](#)] [[PubMed](#)]
5. Derks, J.; Tomasi, C. Peri-implant health and disease. A systematic review of current epidemiology. *J. Clin. Periodontol.* **2015**, *42* (Suppl. 16), S158–S171. [[CrossRef](#)]
6. Carcuac, O.; Berglundh, T. Composition of human peri-implantitis and periodontitis lesions. *J. Dent. Res.* **2014**, *93*, 1083–1088. [[CrossRef](#)] [[PubMed](#)]
7. Derks, J.; Schaller, D.; Håkansson, J.; Wennström, J.L.; Tomasi, C.; Berglundh, T. Peri-implantitis—Onset and pattern of progression. *J. Clin. Periodontol.* **2016**, *43*, 383–388. [[CrossRef](#)] [[PubMed](#)]
8. Xu, L.; Yu, Z.; Lee, H.M.; Wolff, M.S.; Golub, L.M.; Sorsa, T.; Kuula, H. Characteristics of collagenase-2 from gingival crevicular fluid and peri-implant sulcular fluid in periodontitis and peri-implantitis patients: Pilot study. *Acta Odontol. Scand.* **2008**, *66*, 219–224. [[CrossRef](#)] [[PubMed](#)]
9. Fretwurst, T.; Garaicoa-Pazmino, C.; Nelson, K.; Giannobile, W.V.; Squarize, C.H.; Larsson, L.; Castilho, R.M. Characterization of macrophages infiltrating peri-implantitis lesions. *Clin. Oral Implants Res.* **2020**, *31*, 274–281. [[CrossRef](#)]
10. Golub, L.M.; Lee, H.M. Periodontal therapeutics: Current host-modulation agents and future directions. *Periodontology 2000* **2020**, *82*, 186–204. [[CrossRef](#)]
11. Tan, K.C.; Chow, W.S.; Tam, S.; Bucala, R.; Betteridge, J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. *Diabetes Care* **2004**, *27*, 223–228. [[CrossRef](#)]

12. Golub, L.M.; Lee, H.M.; Stoner, J.A.; Sorsa, T.; Reinhardt, R.A.; Wolff, M.S.; Ryan, M.E.; Nummikoski, P.V.; Payne, J.B. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. *J. Periodontol.* **2008**, *79*, 1409–1418. [[CrossRef](#)] [[PubMed](#)]
13. Payne, J.B.; Golub, L.M.; Stoner, J.A.; Lee, H.M.; Reinhardt, R.A.; Sorsa, T.; Slepian, M.J. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: A randomized, double-masked, placebo-controlled clinical trial. *J. Am. Dent. Assoc.* **2011**, *142*, 262–273. [[CrossRef](#)]
14. Payne, J.B.; Golub, L.M. Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic. *Pharmacol. Res.* **2011**, *63*, 121–129. [[CrossRef](#)] [[PubMed](#)]
15. Brown, D.L.; Desai, K.K.; Vakili, B.A.; Nouneh, C.; Lee, H.M.; Golub, L.M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. *Arterioscler Thromb. Vasc. Biol.* **2004**, *24*, 733–738. [[CrossRef](#)]
16. Bench, T.J.; Jeremias, A.; Brown, D.L. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. *Pharmacol. Res.* **2011**, *64*, 561–566. [[CrossRef](#)] [[PubMed](#)]
17. Bassuk, S.S.; Rifai, N.; Ridker, P.M. High-sensitivity C-reactive protein: Clinical importance. *Curr. Probl. Cardiol.* **2004**, *29*, 439–493.
18. Aday, A.W.; Ridker, P.M. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. *Front. Cardiovasc. Med.* **2019**, *6*, 16. [[CrossRef](#)]
19. Golub, L.M.; Stakiw, J.E.; Singer, D.L. Collagenolytic activity of human gingival crevice fluid. *J. Dent. Res.* **1974**, *53*, 1501. [[CrossRef](#)]
20. Ohlsson, K.; Olsson, I.; Tynelius-Bratthall, G. Neutrophil leukocyte collagenase, elastase and serum protease inhibitors in human gingival crevices. *Acta Odontol. Scand.* **1974**, *32*, 51–59. [[CrossRef](#)]
21. Golub, L.M.; Siegel, K.; Ramamurthy, N.S.; Mandel, I.D. Some characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival diseases in humans. *J. Dent. Res.* **1976**, *55*, 1049–1057. [[CrossRef](#)]
22. Golub, L.M.; Kennett, S.; McEwan, H.; Curran, J.B.; Ramamurthy, N.S. Collagenolytic activity of crevicular fluid from pericoronal gingival flaps. *J. Dent. Res.* **1976**, *55*, 177–181. [[CrossRef](#)]
23. Leppilähti, J.M.; Hernández-Ríos, P.A.; Gamonal, J.A.; Tervahartiala, T.; Brignardello-Petersen, R.; Mantyla, P.; Sorsa, T.; Hernández, M. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. *J. Clin. Periodontol.* **2014**, *41*, 348–356. [[CrossRef](#)] [[PubMed](#)]
24. Sorsa, T.; Gursoy, U.K.; Nwhator, S.; Hernandez, M.; Tervahartiala, T.; Leppilähti, J.; Gursoy, M.; Könönen, E.; Emingil, G.; Pussinen, P.J.; et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. *Periodontology 2000* **2016**, *70*, 142–163. [[CrossRef](#)] [[PubMed](#)]
25. Sorsa, T.; Hernández, M.; Leppilähti, J.; Munjal, S.; Netuschil, L.; Mäntylä, P. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. *Oral Dis.* **2010**, *16*, 39–45. [[CrossRef](#)] [[PubMed](#)]
26. Nwhator, S.O.; Ayanbadejo, P.O.; Umezudike, K.A.; Opeodu, O.I.; Agbelusi, G.A.; Olamijulo, J.A.; Arowojolu, M.O.; Sorsa, T.; Babajide, B.S.; Opedun, D.O. Clinical correlates of a lateral-flow immunoassay oral risk indicator. *J. Periodontol.* **2014**, *85*, 188–194. [[CrossRef](#)]
27. Johnson, N.; Ebersole, J.L.; Kryscio, R.J.; Danaher, R.J.; Dawson, D., 3rd; Al-Sabbagh, M.; Miller, C.S. Rapid assessment of salivary MMP-8 and periodontal disease using lateral flow immunoassay. *Oral Dis.* **2016**, *22*, 681–687. [[CrossRef](#)]
28. Sorsa, T.; Gieselmann, D.; Arweiler, N.B.; Hernández, M. A quantitative point-of-care test for periodontal and dental peri-implant diseases. *Nat. Rev. Dis. Primers* **2017**, *3*, 17069. [[CrossRef](#)]
29. Alassiri, S.; Parnanen, P.; Rathnayake, N.; Johannsen, G.; Heikkinen, A.M.; Lazzara, R.; van der Schoor, P.; van der Schoor, J.G.; Tervahartiala, T.; Gieselmann, D.; et al. The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. *Dis. Markers* **2018**, *2018*, 1306396. [[CrossRef](#)]
30. Räisänen, I.T.; Heikkinen, A.M.; Nwhator, S.O.; Umezudike, K.A.; Tervahartiala, T.; Sorsa, T. On the diagnostic discrimination ability of mouthrinse and salivary aMMP-8 point-of-care testing regarding periodontal health and disease. *Diagn. Microbiol. Infect. Dis.* **2019**, *95*, 114871. [[CrossRef](#)]

31. Lähteenmäki, H.; Umezudike, K.A.; Heikkinen, A.M.; Räisänen, I.T.; Rathnayake, N.; Johannsen, G.; Tervahartiala, T.; Nwhator, S.O.; Sorsa, T. aMMP-8 Point-of-Care/Chairside Oral Fluid Technology as a Rapid, Non-Invasive Tool for Periodontitis and Peri-Implantitis Screening in a Medical Care Setting. *Diagnostics* **2020**, *10*, 562. [[CrossRef](#)]
32. Ozçaka, O.; Biçakci, N.; Pussinen, P.; Sorsa, T.; Köse, T.; Buduneli, N. Smoking and matrix metalloproteinases, neutrophil elastase and myeloperoxidase in chronic periodontitis. *Oral Dis.* **2011**, *17*, 68–76. [[CrossRef](#)]
33. Sorsa, T.; Alassiri, S.; Grigoriadis, A.; Räisänen, I.T.; Pärnänen, P.; Nwhator, S.O.; Gieselmann, D.R.; Sakellari, D. Active MMP-8 (aMMP-8) as a Grading and Staging Biomarker in the Periodontitis Classification. *Diagnostics* **2020**, *10*, 61. [[CrossRef](#)] [[PubMed](#)]
34. Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J. Clin. Periodontol.* **2018**, *45* (Suppl. 20), S149–S161. [[CrossRef](#)]
35. Nieminen, M.T.; Vesterinen, P.; Tervahartiala, T.; Kormi, I.; Sinisalo, J.; Pussinen, P.J.; Sorsa, T. Practical implications of novel serum ELISA-assay for matrix metalloproteinase-8 in acute cardiac diagnostics. *Acute Card Care* **2015**, *17*, 46–47. [[CrossRef](#)] [[PubMed](#)]
36. Dreyer, H.; Grischke, J.; Tiede, C.; Eberhard, J.; Schweitzer, A.; Toikkanen, S.E.; Glöckner, S.; Krause, G.; Stiesch, M. Epidemiology and risk factors of peri-implantitis: A systematic review. *J. Periodontal Res.* **2018**, *53*, 657–681. [[CrossRef](#)] [[PubMed](#)]
37. Kordbacheh Changi, K.; Finkelstein, J.; Papapanou, P.N. Peri-implantitis prevalence, incidence rate, and risk factors: A study of electronic health records at a U.S. dental school. *Clin. Oral Implants Res.* **2019**, *30*, 306–314. [[CrossRef](#)] [[PubMed](#)]
38. Becker, S.T.; Beck-Broichsitter, B.E.; Graetz, C.; Dörfer, C.E.; Wiltfang, J.; Häsler, R. Peri-implantitis versus periodontitis: Functional differences indicated by transcriptome profiling. *Clin. Implant. Dent. Relat. Res.* **2014**, *16*, 401–411. [[CrossRef](#)] [[PubMed](#)]
39. Salvi, G.E.; Cosgarea, R.; Sculean, A. Prevalence and Mechanisms of Peri-implant Diseases. *J. Dent. Res.* **2017**, *96*, 31–37. [[CrossRef](#)]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).